Atpoint Tx

Washington DC-based biotech startup dedicated to innovating cell-based technologies for treatments at the point-of-care. We believe in the possibility of patients becoming "self-repairing" by using their OWN stem cells to replenish and restore cells in degenerative diseases that have undergone damage. Cellular therapy is 10-15% of all clinical applications today and only rising with an aging population. Led by a team of scientists, our founders and members have previously succeeded in utilizing iterative iPSC technologies for rapid tissue-specific regeneration, and patient-specific primary cellular applications sanctioned by the FDA for investigational use in phase I clinical trials. Our team is innovating novel devices and applications using AI modeling to leverage personalized stem cell therapies for disease-specific needs. Currently approaching our next round, we are dedicated to enhancing stem cell treatment paradigms by changing the face of stem cell technologies at bed-side.